Gerri Henwood
President/CEO
Ms. Henwood is the President/CEO of Recro Pharma and is President/Founder of Malvern Consulting Group. She was the President and CEO of Auxilium Pharmaceuticals, Inc (NASDAQ: AUXL), a company she founded in late 1999. She raised $90 million in private equity and was able to take the company public in August 2004. As of December 31, 2009, Auxilium's market capitalization exceeded $1.3 billion. Ms. Henwood successfully shepherded this start-up company through the drug development stage to its current position with one drug on the market and several more in late stage development and trailing 12 month revenues exceeding $60 million.

From 1985-1999, Ms. Henwood was the founder and CEO of IBAH, a contract research organization. IBAH reached a net revenue level of $150 million, as a NASDAQ traded company, before being acquired by Omnicare in 1998.

Ms. Henwood began her career with Smith Kline & French, now part of Glaxo SmithKline PLC, in the pharmaceutical marketing department. She rose through the ranks at Smith Kline & French to be the head of Regulatory and Medical Affairs for the U.S. business and then to the position of Group Director – Marketing in the International Pharmaceutical Division.

Ms. Henwood currently serves on the Board of Directors of Alkermes, Inc. (NASDAQ:ALKS), Garnet BioTherapeutics, Inc. (private), MAP Pharmaceuticals, Inc. (private) and is a member of the Board of Trustees for LaSalle Academy, an elementary school for "at risk" youth, in Philadelphia, PA. Ms. Henwood holds a B.S. degree from Neumann College.

Randy Mack
Executive Vice President, Development
Mr. Mack currently serves as the Executive Vice President, Development for Recro Pharma. Previously, he served as Vice President, Project Management and Operations at Adolor Corporation where he oversaw the development programs in the areas of opioid-induced bowel dysfunction and pain management. For more than 15 years he has also held positions of increasing responsibilities at Auxilium Pharmaceuticals, Abbott Laboratories and Harris Laboratories. In these positions he was responsible for the conduct of over 400 clinical trials, filing of 20 INDs and 4 NDAs. During his career he has authored more than 75 scientific articles, book chapters, abstracts and poster presentations in the areas of gastroenterology, urology, neuroscience and psychiatric disorders. Mr. Mack holds a BS in biology and chemistry from the University of Nebraska-Lincoln.

Diane Myers
Senior Vice President,
Regulatory Affairs & Quality Assurance
Ms. Myers joined Recro Pharma, Inc. in October 2008 as Senior Vice President of Regulatory Affairs and Quality Assurance.  She has over 25 years of pharmaceutical experience working for both large and small pharmaceutical companies.  Ms. Myers had served as Vice President Regulatory Affairs and Quality at Auxilium Pharmaceuticals, Inc. for 8 years prior to joining Recro Pharma. In addition, for more than 15 years she held positions of increasing responsibility at GlaxoSmithKline in the QC and QA groups within the Biopharmaceutical R & D Division. She holds a BS in Biology from Neumann University.

John Rodzvilla, M.D.
Vice President, Medical Affairs
Dr. Rodzvilla currently serves as Vice President of Medical Affairs at Recro Pharma. He is a graduate of Thomas Jefferson Medical School and completed his residency in pediatrics and his fellowship in Ambulatory Pediatrics at Mercy Catholic Medical Center and Children's Hospital of Philadelphia, obtaining his Board Certification in Pediatrics. He practiced pediatrics in the Philadelphia area and was involved as an investigator in trials for the development of several vaccines and establishment of doses, effectiveness and safety of several drugs used in pediatrics. Subsequently, Dr. Rodzvilla joined Auxilium Pharmaceuticals and served there in several capacities; Medical Safety Officer, VP of Medical Affairs, VP of Medical-Clinical Development and was an integral part of the teams that developed Testim® Transdermal Gel and Xiaflex® Injection. He has experience in all phases of drug development including interaction with regulatory agencies, non-clinical development, clinical development, drug safety, advisory board preparation, and marketed drugs. Dr. Rodzvilla has multiple publications and has served as medical consultant to the industry and speaker at training seminars for the industry.

Karen Cashmere
Vice President, Marketing
Karen Cashmere is a marketing & management executive with over 20 years' experience driving strategic growth and product visibility for Fortune 500, mid-size and small, clinical stage start-up biopharmaceutical companies. Her areas of expertise include strategic planning, life cycle management, business development, and product management (new and mature products). Throughout her career, Karen has launched 4 new pharmaceutical products and numerous pharmaceutical line extensions. Prior to joining Recro Pharma, Karen was Senior Vice President of New Product Marketing at Auxilium Pharmaceuticals, in which she was responsible for pipeline planning and pre-launch/launch strategic planning and implementation for Xiaflex®, a biologic with numerous potential orphan indications, including Dupuytren's contracture and Peyronie's disease. Karen began her career at Abbott and has held positions of increasing responsibility within Abbott and at EMS Serono, now part of Merck KGaA, Noven Pharmaceuticals (joint venture with Novartis), and Andrx Pharmaceuticals (Branded Division), now Watson.

Christopher T. Sharr
Vice President, Manufacturing
Mr. Sharr's current position is Vice President of Manufacturing for Recro Pharma, Inc.  Previously, he was Director, Manufacturing at Auxilium Pharmaceuticals, Inc., and was responsible for overall manufacturing, testing and distribution of the commercial product Testim® (1% testosterone gel).  Mr. Sharr was also closely involved in the drug product development, manufacturing, clinical packaging and distribution of Xiaflex®.  Prior to his experience at Auxilium, Mr. Sharr spent over 7 years working for IBAH Pharmaceutics, Inc., a contract research organization, which later became Omnicare Pharmaceutics, Inc.  While at IBAH, he held positions of increasing responsibilities in the area of clinical manufacturing and packaging.  Mr. Sharr has over 13 years experience related to the development and commercialization of chemical and biological drug products.  Mr. Sharr holds a BS in Business Administration from Neumann University.

Christopher Barber
Director, Quality Assurance
Mr. Barber's current position is Director of Quality Assurance for Recro Pharma, Inc.  Previously, he was Quality Assurance Manager at Auxilium Pharmaceuticals, Inc., and was responsible for overall compliance of the commercial product Testim® (1% testosterone gel). Mr. Barber was also closely involved with the drug product development and preparation for commercialization of Xiaflex®.  Prior to working at Auxilium he spent over 5 years working at GlaxoSmithKline holding positions of increasing responsibilities in the area of Quality Assurance and Quality Control.  Mr. Barber has over 13 years quality and analytical experience related to the development and commercialization of chemical and biological drug products.  He holds a BS in Biology: Microbiology from West Chester University.  

Rachel Reeves
Director, Development Operations
Rachel Reeves joined Recro Pharma in January 2009 as Director, Development Operations.   She has over 15 years of management experience in various roles working with Bio-Pharm/IBAH, Focused Managed Research, RapidTrials, and most recently as Director, Clinical Operations and Monitoring for Clinlogix.  Rachel is also working towards her Bachelor's Degree from Neumann University.

Melissa Brookes
Director, Development
Melissa Brookes is Director, Development for Recro Pharma with a focus in Project Management.  She was previously an Associate Director, Clinical Development at Ascenta Therapeutics where she managed cross-functional project teams and clinical trial operations.  For more than 10 years, she has also held positions in US and global clinical trial management at Titan Pharmaceuticals and Genentech. 

Donna Nichols
Corporate Controller
Before joining Recro Pharma, Ms. Nichols worked at Auxilium Pharmaceuticals as the Director of Accounting from July 2008-March 2009 and as Accounting Manager from February 2004-June 2008. She was the Director of Financial Reporting at Adolor Corporation from November 2000-June 2003 where she was part of the team that took the company through an IPO. She had worked for the company as a consultant from August 1996-November 2000. As a consultant, she was able to work with many different start -up companies. Prior to moving to Pennsylvania, she had worked for CPA firms in Maryland and New Jersey. Ms. Nichols received a B.S. degree from Rider University and is a Certified Public Accountant in Pennsylvania and Maryland.

Alex Freyer, Pharm.D.
Clinical Scientist
Alex joined Recro Pharma after graduating from Temple University School of Pharmacy in 2009. With Recro he has worked in the development of clinical and preclinical studies, performed pharmacokinetic modeling and calculations, and prepared clinical study reports, IND filings, FDA briefing materials and clinical literature summaries. Alex is also a licensed pharmacist in the state of Pennsylvania.